 Daré Bioscience, Inc. DARE, a leader in womens health innovation, today announced the receipt by its wholly owned subsidiary of 1.5 million in additional grant funding from the Bill Melinda Gates Foundation. The grant supports ongoing development activities in 2020 for its user-controlled long acting reversible contraceptive program, referred to as DARE-LARC1. DARE-LARC1 has been developed with the support from the foundation in the form of approximately 18 million in grant funding prior to this most recent disbursement. 